Global Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market

The global Chronic Obstructive Pulmonary Disease (COPD) diagnosis market is witnessing robust market growth driven by rising COPD incidence and innovation in diagnostic modalities. Industry size has expanded as companies invest in portable devices and AI-enabled imaging, addressing critical market challenges such as underdiagnosis in underserved regions. Market insights from recent analysis highlight evolving Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market dynamics and emerging market opportunities, setting the stage for sustained business growth over the forecast period.

Market Size and Overview

The chronic obstructive pulmonary disease (COPD) diagnosis market is estimated to be valued at USD 2.29 billion in 2025 and is expected to reach USD 3.24 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

This Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market report outlines expanding market segments, driven by advanced spirometry, imaging, and biomarker technologies, boosting total Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market revenue and industry share in developed regions. Market forecast models indicate demand surge in emerging economies despite market restraints such as reimbursement challenges and infrastructure gaps. Evolving market trends highlight a shift toward portable diagnostics and digital monitoring solutions.

Investment Scenario

The Chronic Obstructive Pulmonary Disease (COPD) Diagnosis market is attracting significant capital allocation shifts toward diagnostic innovation and digital health. According to our 2025 market report, venture capital firms led by HealthTech Ventures closed USD 45 million in a Series B round for portable spirometry in Q2 2025, underscoring rising investor confidence. Strategic M&A deals include a 2025 acquisition of a biomarker analytics startup by Roche Diagnostics for USD 320 million, enhancing diagnostic assay portfolios and augmenting market revenue streams. Public funding saw a 12% boost under EU Horizon programs to support AI-driven imaging tools, reflecting growing market research interest and reinforcing market growth strategies.

Regional Opportunities

• North America: U.S. COPD diagnosis exports rose 8% in 2024, driven by CMS reimbursement reforms; new FDA approvals for portable spirometers signal robust market opportunities and favorable policy dynamics.
• Asia Pacific: China’s investment in three provincial diagnostic hubs (2025) and India’s public–private diagnostic alliances are expanding market scope, addressing regional market challenges and boosting market share in rural screening.
• Europe: Germany’s €50 million initiative under EU’s Digital Health Act (2025) for tele-diagnosis infrastructure, alongside the entry of local suppliers in Spain, underscores strong demand in underserved segments and positive Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market trends.

Key Players

Key market players (market companies) impacting Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market share include:
- GSK: Brazil hub launch (2025), awareness drive; capacity +5%.
- AstraZeneca: Expanded China distribution (2024), invested in AI imaging; market reach +8%.
- Boehringer Ingelheim: Acquired biomarker startup (2025), built India R&D center.
- Novartis: US tele-diagnosis pilot (2025), partnered with 3 clinics; usage +12%.
- Teva Pharmaceutical: Launched portable spirometers (2024); secured USD 25 M funding.
- Roche Diagnostics: Acquired AI spirometry tech (2025), opened Europe hub.
- Philips Healthcare: Invested USD 40 M in digital diagnostics (2025); user base +10%.
- Siemens Healthineers: China production facility opened (2024); export +15%.
- GE Healthcare: Partnered with APAC hospitals (2025); training programs deployed.
- Abbott Laboratories: Telehealth platform rollout (2024); joint venture in Latin America.
- Becton Dickinson: Launched biomarker assays (2025); secured FDA clearance.
- CareDx: Series A USD 20 M round (2025); expanded to EU markets.

FAQs

1. Who are the dominant players in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
Key players include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceutical, Roche Diagnostics, Philips, Siemens Healthineers, GE Healthcare, Abbott, Becton Dickinson, and CareDx.

2. What will be the size of the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market in the coming years?
The market is projected to grow from USD 2.29 Bn in 2025 to USD 3.24 Bn by 2032 at a CAGR of 5.1%.

3. Which end-user segment has the largest growth opportunity?
Hospital and clinical laboratory segments lead, driven by early screening mandates, centralized diagnostic platforms, and integration of digital reporting systems.

4. How will market development trends evolve over the next five years?
Advances will center on AI-enabled imaging, portable spirometry, biomarker panels, telehealth integration, and point-of-care digital dashboards for remote COPD management.

5. What is the nature of the competitive landscape and challenges in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
The landscape features intense R&D race, strategic acquisitions, and partnerships; challenges include high device costs, reimbursement complexities, and regulatory hurdles across regions.

6. What go-to-market strategies are commonly adopted in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
Players leverage strategic partnerships with healthcare providers, regional production hubs, digital marketing campaigns, value-based pricing, and integration with telehealth platforms.

➢Get More Insights On: Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market

➢Get this Report in Japanese Language: 慢性閉塞性肺疾患（COPD）診断市場

➢Get this Report in Korean Language: 만성폐쇄성폐질환(COPD)진단시장

➢Read More Related Articles- The Emerging cGAS-STING Pathway is Poised for Growth

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)